Clinical Trial

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 25, 2022 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-08.
Trial Details
NCT Number NCT05244798
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Collaborators: Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Hebei Medical University Fourth Hospital, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Anyang Tumor Hospital, Shantou Central Hospital, Innovent Biologics (Suzhou) Co. Ltd., GeneCast Biotechnology Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 420 participants
Start Date 2022-11-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-10-25